Literature DB >> 23027656

Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.

Jian Ma1, Yanpeng Wang, Dong Zheng, Meng Wei, Huaxi Xu, Tianqing Peng.   

Abstract

AIMS: Doxorubicin causes damage to the heart, often leading to irreversible cardiomyopathy, which is fatal. Reactive oxygen species (ROS) or oxidative stress is involved in cardiomyocyte death, contributing to doxorubicin-induced cardiotoxicity. This study investigated the role of Rac1, an important subunit of NADPH oxidase, in doxorubicin-induced cardiotoxicity and the underlying mechanisms. METHODS AND
RESULTS: In a mouse model of acute doxorubicin-induced cardiotoxicity, cardiomyocyte-specific deletion of Rac1 inhibited NADPH oxidase activation and ROS production, prevented cardiac cell death, and improved myocardial function in Rac1 knockout mice. Therapeutic administration of the specific Rac1 inhibitor NSC23766 achieved similar cardio-protective effects in doxorubicin-stimulated mice. In rat cardiomyoblasts (H9c2 cells) and cultured neonatal mouse cardiomyocytes, Rac1 inhibition attenuated apoptosis as evidenced by decreases in caspase-3 activity and DNA fragmentation in response to doxorubicin, which correlated with a reduction in ROS production and down-regulation of p53 acetylation and histone H2AX phosphorylation. In contrast, overexpression of Rac1 enhanced apoptosis. Doxorubicin also inhibited the activity of classical histone deacetylases (HDAC), which was preserved by Rac1 inhibition and further decreased by Rac1 overexpression. Interestingly, scavenging ROS mitigated apoptosis but did not change HDAC activity and p53 acetylation stimulated by doxorubicin, suggesting both ROS-dependent and -independent pathways are involved in Rac1-mediated cardiotoxicity. Furthermore, the HDAC inhibitor trichostatin A enhanced apoptosis, p53 acetylation and H2AX phosphorylation in doxorubicin-treated cardiomyocytes.
CONCLUSIONS: Rac1 signalling contributes to doxorubicin-induced cardiotoxicity through both a ROS-dependent mechanism and ROS-independent HDAC/p53 signalling in cardiomyocytes. Thus, inhibition of Rac1 may be a useful therapy for doxorubicin-induced cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027656     DOI: 10.1093/cvr/cvs309

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  45 in total

1.  Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity.

Authors:  Dong Zheng; Yi Zhang; Ming Zheng; Ting Cao; Grace Wang; Lulu Zhang; Rui Ni; Joseph Brockman; Huiting Zhong; Guo-Chang Fan; Tianqing Peng
Journal:  Clin Sci (Lond)       Date:  2019-07-15       Impact factor: 6.124

Review 2.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

3.  HSP25 down-regulation enhanced p53 acetylation by dissociation of SIRT1 from p53 in doxorubicin-induced H9c2 cell apoptosis.

Authors:  Chi Zhang; Shunlin Qu; Xing Wei; Yansheng Feng; Honglin Zhu; Jia Deng; Kangkai Wang; Ke Liu; Meidong Liu; Huali Zhang; Xianzhong Xiao
Journal:  Cell Stress Chaperones       Date:  2015-10-29       Impact factor: 3.667

4.  Salvianolic acid B protects against doxorubicin induced cardiac dysfunction via inhibition of ER stress mediated cardiomyocyte apoptosis.

Authors:  Rongchang Chen; Guibo Sun; Longpo Yang; Jian Wang; Xiaobo Sun
Journal:  Toxicol Res (Camb)       Date:  2016-06-06       Impact factor: 3.524

Review 5.  The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system.

Authors:  Thomas Kietzmann; Andreas Petry; Antonina Shvetsova; Joachim M Gerhold; Agnes Görlach
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

6.  Ataxia telangiectasia mutated in cardiac fibroblasts regulates doxorubicin-induced cardiotoxicity.

Authors:  Hong Zhan; Kenichi Aizawa; Junqing Sun; Shota Tomida; Kinya Otsu; Simon J Conway; Peter J Mckinnon; Ichiro Manabe; Issei Komuro; Kiyoshi Miyagawa; Ryozo Nagai; Toru Suzuki
Journal:  Cardiovasc Res       Date:  2016-02-09       Impact factor: 10.787

7.  Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress.

Authors:  Hong Zhu; Soumyadeep Sarkar; Laura Scott; Igor Danelisen; Michael A Trush; Zhenquan Jia; Y Robert Li
Journal:  React Oxyg Species (Apex)       Date:  2016

8.  Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy.

Authors:  Rui Ni; Ting Cao; Sidong Xiong; Jian Ma; Guo-Chang Fan; James C Lacefield; Yanrong Lu; Sydney Le Tissier; Tianqing Peng
Journal:  Free Radic Biol Med       Date:  2015-11-11       Impact factor: 7.376

9.  ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.

Authors:  Frances Belmonte; Samarjit Das; Polina Sysa-Shah; Vidhya Sivakumaran; Brian Stanley; Xin Guo; Nazareno Paolocci; Miguel A Aon; Masaki Nagane; Periannan Kuppusamy; Charles Steenbergen; Kathleen Gabrielson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

10.  Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.

Authors:  Sundar Kumar Kondru; Ajay Godwin Potnuri; Lingesh Allakonda; Prasad Konduri
Journal:  Mol Cell Biochem       Date:  2017-09-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.